Updating results

1226 results

Sort: Relevance | Date

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published April 2019

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Technology appraisal guidance Published June 2019

Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293)

Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune (idiopathic) thrombocytopenic purpura (chronic ITP)

Technology appraisal guidance Published July 2013 Last updated October 2018

Ranibizumab for treating diabetic macular oedema (TA274)

Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema

Technology appraisal guidance Published February 2013

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

Technology appraisal guidance Published February 2013

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance Published March 2013

Omalizumab for treating severe persistent allergic asthma (TA278)

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma

Technology appraisal guidance Published April 2013

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Technology appraisal guidance Published April 2013

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published May 2013

Alteplase for treating acute ischaemic stroke (TA264)

Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)

Technology appraisal guidance Published September 2012

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)

Technology appraisal guidance Published November 2012

Ivabradine for treating chronic heart failure (TA267)

Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure

Technology appraisal guidance Published November 2012

Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced (unresectable or metastatic) melanoma

Technology appraisal guidance Published December 2012

Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of

Technology appraisal guidance Published May 2013

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

Technology appraisal guidance Published June 2013 Last updated November 2016

Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)

Evidence-based recommendations on the use of fludarabine for B-cell chronic lymphocytic leukaemia (CLL)

Technology appraisal guidance Published September 2001

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance Published July 2013

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel

Technology appraisal guidance Published June 2012 Last updated July 2016

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine

Technology appraisal guidance Published June 2012

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published August 2012

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

Evidence-based recommendations on lapatinib (Tyverb) or trastuzumab (Herceptin) combined with an aromatase inhibitor for the first-line treatment of..

Technology appraisal guidance Published June 2012

Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)

Evidence-based recommendations on erlotinib (Tarceva) for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published June 2012

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)

Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Technology appraisal guidance Published January 2013

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance Published May 2013

Golimumab for the treatment of psoriatic arthritis (TA220)

Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis

Technology appraisal guidance Published April 2011

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated October 2018

Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

Evidence-based recommendations on cilostazol (Pletal), naftidrofuryl oxalate (Praxilene), pentoxifylline (Trental 400) and inositol nicotinate (Hexopal)

Technology appraisal guidance Published May 2011

Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

Evidence-based recommendations on fulvestrant (Faslodex) for treating locally advanced or metastatic breast cancer

Technology appraisal guidance Published December 2011

Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer..

Technology appraisal guidance Published January 2012

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of stage III–IV follicular lymphoma

Technology appraisal guidance Published January 2012

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults

Technology appraisal guidance Published January 2012

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease

Technology appraisal guidance Published March 2011 Last updated June 2018

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance Published March 2011

Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published July 2011

Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Technology appraisal guidance Published April 2001 Last updated March 2016

Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

Evidence-based recommendations on bivalirudin (Angiox) for treating ST-segment-elevation myocardial infarction (STEMI)

Technology appraisal guidance Published July 2011

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)

Evidence-based recommendations on aripiprazole (Abilify) for treating schizophrenia in people aged 15 to 17 years

Technology appraisal guidance Published January 2011

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

Evidence-based recommendations on bevacizumab (Avastin) in combination with a taxane for the first-line treatment of metastatic breast cancer

Technology appraisal guidance Published February 2011

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Evidence-based recommendations on bendamustine (Levact) for the first-line treatment of chronic lymphocytic leukaemia (CLL) of Binet stage B or C

Technology appraisal guidance Published February 2011

Mifamurtide for the treatment of osteosarcoma (TA235)

Evidence-based recommendations on mifamurtide (Mepact) for treatment of osteosarcoma (bone cancer)

Technology appraisal guidance Published October 2011

Ticagrelor for the treatment of acute coronary syndromes (TA236)

Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes

Technology appraisal guidance Published October 2011

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)

Evidence-based recommendations on tocilizumab (RoActemra) for treating systemic juvenile idiopathic arthritis

Technology appraisal guidance Published December 2011

Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs

Technology appraisal guidance Published June 2011

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma (TA226)

Evidence-based recommendations on rituximab (MabThera) for first-line maintenance treatment of follicular non-Hodgkin's lymphoma

Technology appraisal guidance Published June 2011